CN115298175B - 可用作免疫抑制剂的大环pad4抑制剂 - Google Patents
可用作免疫抑制剂的大环pad4抑制剂 Download PDFInfo
- Publication number
- CN115298175B CN115298175B CN202180022507.5A CN202180022507A CN115298175B CN 115298175 B CN115298175 B CN 115298175B CN 202180022507 A CN202180022507 A CN 202180022507A CN 115298175 B CN115298175 B CN 115298175B
- Authority
- CN
- China
- Prior art keywords
- substituted
- alkyl
- alkylene
- group
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed systems contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062970832P | 2020-02-06 | 2020-02-06 | |
| US62/970,832 | 2020-02-06 | ||
| PCT/US2021/016698 WO2021158840A1 (en) | 2020-02-06 | 2021-02-05 | Macrocyclic pad4 inhibitors useful as immunosuppressant |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN115298175A CN115298175A (zh) | 2022-11-04 |
| CN115298175B true CN115298175B (zh) | 2024-05-07 |
Family
ID=74798090
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202180022507.5A Active CN115298175B (zh) | 2020-02-06 | 2021-02-05 | 可用作免疫抑制剂的大环pad4抑制剂 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US12492202B2 (cg-RX-API-DMAC10.html) |
| EP (1) | EP4100405A1 (cg-RX-API-DMAC10.html) |
| JP (1) | JP7711073B2 (cg-RX-API-DMAC10.html) |
| KR (1) | KR20220137694A (cg-RX-API-DMAC10.html) |
| CN (1) | CN115298175B (cg-RX-API-DMAC10.html) |
| WO (1) | WO2021158840A1 (cg-RX-API-DMAC10.html) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115298175B (zh) | 2020-02-06 | 2024-05-07 | 百时美施贵宝公司 | 可用作免疫抑制剂的大环pad4抑制剂 |
| TW202140477A (zh) | 2020-02-12 | 2021-11-01 | 美商必治妥美雅史谷比公司 | 雜環pad4抑制劑 |
| MX2022013615A (es) | 2020-04-30 | 2022-11-16 | Gilead Sciences Inc | Inhibidores de macrociclo de peptidilarginina deiminasas. |
| EP4267562A1 (en) | 2020-12-22 | 2023-11-01 | Gilead Sciences, Inc. | Inhibitors of peptidylarginine deiminases |
| TW202233174A (zh) | 2020-12-22 | 2022-09-01 | 美商基利科學股份有限公司 | 肽基精胺酸去亞胺酶之抑制劑 |
| WO2025024265A1 (en) | 2023-07-21 | 2025-01-30 | Bristol-Myers Squibb Company | Methods of assessing citrullination and activity of pad4 modulators |
| WO2026020127A2 (en) | 2024-07-19 | 2026-01-22 | Bristol-Myers Squibb Company | Methods of assessing citrullination and activity of pad2 modulators |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104470919A (zh) * | 2012-07-26 | 2015-03-25 | 葛兰素集团有限公司 | 作为pad4抑制剂的2-(氮杂吲哚-2-基)苯并咪唑 |
| CN108601770A (zh) * | 2015-12-09 | 2018-09-28 | 帕德罗科治疗公司 | Pad4的氮杂-苯并咪唑抑制剂 |
| CN109069869A (zh) * | 2015-12-09 | 2018-12-21 | 帕德罗科治疗公司 | 双环pad4抑制剂 |
| CN109790162A (zh) * | 2016-07-27 | 2019-05-21 | 帕德罗科治疗公司 | Pad4的共价抑制剂 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016185279A1 (en) * | 2015-05-21 | 2016-11-24 | Glaxosmithkline Intellectual Property Development Limited | Benzoimidazole derivatives as pad4 inhibitors |
| SG11201807021UA (en) | 2016-02-23 | 2018-09-27 | Padlock Therapeutics Inc | Heteroaryl inhibitors of pad4 |
| KR102502992B1 (ko) | 2016-09-12 | 2023-02-24 | 패들락 테라퓨틱스, 인코포레이티드 | Pad4의 헤테로아릴 억제제 |
| ES2929200T3 (es) | 2018-08-08 | 2022-11-25 | Bristol Myers Squibb Co | Tienopirroles sustituidos como inhibidores de PAD4 |
| MX2021001471A (es) | 2018-08-08 | 2021-04-28 | Bristol Myers Squibb Co | Benzimidazoles sustituidos como inhibidores de peptidil arginina deiminasa 4 (pad4). |
| EP3833440A1 (en) | 2018-08-08 | 2021-06-16 | Bristol-Myers Squibb Company | Indole and azaindole inhibitors of pad enzymes |
| ES2956090T3 (es) | 2018-08-08 | 2023-12-13 | Bristol Myers Squibb Co | Inhibidores de bencimidazol de enzimas PAD |
| CN115298175B (zh) | 2020-02-06 | 2024-05-07 | 百时美施贵宝公司 | 可用作免疫抑制剂的大环pad4抑制剂 |
| TW202140477A (zh) | 2020-02-12 | 2021-11-01 | 美商必治妥美雅史谷比公司 | 雜環pad4抑制劑 |
-
2021
- 2021-02-05 CN CN202180022507.5A patent/CN115298175B/zh active Active
- 2021-02-05 KR KR1020227030292A patent/KR20220137694A/ko active Pending
- 2021-02-05 EP EP21708867.3A patent/EP4100405A1/en active Pending
- 2021-02-05 WO PCT/US2021/016698 patent/WO2021158840A1/en not_active Ceased
- 2021-02-05 US US17/760,309 patent/US12492202B2/en active Active
- 2021-02-05 JP JP2022547846A patent/JP7711073B2/ja active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104470919A (zh) * | 2012-07-26 | 2015-03-25 | 葛兰素集团有限公司 | 作为pad4抑制剂的2-(氮杂吲哚-2-基)苯并咪唑 |
| CN108601770A (zh) * | 2015-12-09 | 2018-09-28 | 帕德罗科治疗公司 | Pad4的氮杂-苯并咪唑抑制剂 |
| CN109069869A (zh) * | 2015-12-09 | 2018-12-21 | 帕德罗科治疗公司 | 双环pad4抑制剂 |
| CN109790162A (zh) * | 2016-07-27 | 2019-05-21 | 帕德罗科治疗公司 | Pad4的共价抑制剂 |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2023512557A (ja) | 2023-03-27 |
| WO2021158840A1 (en) | 2021-08-12 |
| US12492202B2 (en) | 2025-12-09 |
| US20230203039A1 (en) | 2023-06-29 |
| JP7711073B2 (ja) | 2025-07-22 |
| EP4100405A1 (en) | 2022-12-14 |
| KR20220137694A (ko) | 2022-10-12 |
| CN115298175A (zh) | 2022-11-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN112566916B (zh) | 作为pad4抑制剂的经取代的噻吩并吡咯 | |
| CN112805067B (zh) | Pad酶的吲哚及氮杂吲哚抑制剂 | |
| JP7711073B2 (ja) | 免疫抑制剤として有用な大環状pad4阻害剤 | |
| JP7434281B2 (ja) | Pad酵素のベンズイミダゾール阻害剤 | |
| AU2021273566A1 (en) | Imidazopyrrolopyridine as inhibitors of the JAK family of kinases | |
| JP7483678B2 (ja) | Pad4阻害剤としての置換ベンズイミダゾール | |
| EP3704114A1 (en) | Spirocyclic compounds as farnesoid x receptor modulators | |
| WO2026075941A1 (en) | Pyridazinone derivatives as pad4 inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |